TLDR AH-001 could be a safer and more effective treatment for hair loss.
AH-001, a novel androgen receptor (AR) degrader, shows significant promise as a treatment for androgenetic alopecia (AGA). The study highlights that AH-001 effectively degrades AR protein in VCaP cells at low nanomolar concentrations and reverses DHT-induced hair loss in a murine model with minimal systemic exposure. Importantly, AH-001 did not cause serious adverse effects or local skin irritation, addressing common issues with current AGA treatments like minoxidil and finasteride. This suggests AH-001 could be a safer and more effective option for managing AGA.
23 citations,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
1 citations,
May 2017 in “InTech eBooks” Hair loss in Androgenetic alopecia (AGA) is due to altered cell sensitivity to hormones, not increased hormone levels. Hair growth periods shorten over time, causing hair to become thinner and shorter. This is linked to miscommunication between cell pathways in hair follicles. There's also a change in gene expression related to blood vessels and cell growth in balding hair follicles. The exact molecular causes of AGA are still unclear.
196 citations,
May 2001 in “The journal of investigative dermatology/Journal of investigative dermatology” Sebocytes play a key role in controlling androgen levels in human skin.
November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
